公开(公告)号：US20240025992A1

公开(公告)日：2024-01-25

申请号：US18249807

申请日：2021-10-21

Applicant: Janssen Biotech, Inc.

Inventor： Danlin YANG ,  Sanjaya SINGH ,  Scott R. BRODEUR ,  Jill M. CARTON ,  Rajkumar GANESAN ,  Jennifer HERTZOG ,  Theresa MCDEVITT ,  Kristen M. PICHA ,  Ryan M. SMITH ,  Adam ZWOLAK ,  Sathyadevi VENKATARAMANI ,  Gordon D. POWERS

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  A61K49/00

CPC classification number: C07K16/28 ,  A61K47/6849 ,  C07K16/2809 ,  C07K2319/30 ,  A61K49/0002 ,  C07K2317/622 ,  C07K2317/31 ,  A61P35/00

Abstract: Antibodies and antigen binding regions that bind delta-like protein 3 (DLL3) are described. Multispecific antigen-binding constructs, such as bispecific antibodies, containing the antigen-binding regions that bind to DLL3 are also described. The application also describes methods of treatment or detection using the anti-DLL3 antibodies, antigen-binding fragments or multispecific antigen-binding constructs thereof, and related molecules, compositions and methods.

公开(公告)号：US20220064254A1

公开(公告)日：2022-03-03

申请号：US16936719

申请日：2020-07-23

Applicant: Janssen Biotech, Inc.

Inventor： Raymond BRITTINGHAM ,  Rajkumar GANESAN ,  Sherry LA PORTE ,  John T. LEE ,  Jinquan LUO ,  Theresa MCDEVITT ,  Fei SHEN ,  Sanjaya SINGH ,  Degang SONG ,  Sathyadevi VENKATARAMANI ,  Fang YI ,  Yonghong ZHAO

IPC: C07K14/725 ,  A61K35/17 ,  C07K16/40 ,  C07K14/705

Abstract: The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a human Kallikrein-2 (hK2), and immunoresponsive cells comprising such CARs, for the treatment of cancer.

公开(公告)号：US20250099635A1

公开(公告)日：2025-03-27

申请号：US18832652

申请日：2023-01-25

Applicant: Janssen Biotech, Inc.

Inventor： Fei SHEN ,  Theresa MCDEVITT ,  Shalom GOLDBERG ,  Kristen WILLEY ,  Ryan M. SMITH ,  Sathyadevi VENKATARAMANI

IPC: A61K51/10

Abstract: Provided herein are immunoconjugates, such as radioimmunoconjugates, comprising a therapeutic moiety conjugated to an antibody or antigen binding domain with binding specificity for hK2. In certain embodiments, the hK2-specific immunoconjugate demonstrates a short half-life. Also provided herein are methods of using the immunoconjugates for selectively targeting cancer cells and for treating diseases such as prostate cancer.

公开(公告)号：US20220356266A1

公开(公告)日：2022-11-10

申请号：US17233021

申请日：2021-04-16

Applicant: JANSSEN BIOTECH, INC.

Inventor： Rajkumar GANESAN ,  Adam ZWOLAK ,  Jason HO ,  Natasa OBERMAJER ,  Michael DIEM ,  Sanjaya SINGH ,  Sathyadevi VENKATARAMANI ,  Theresa MCDEVITT ,  Fei SHEN

IPC: C07K16/30 ,  C07K16/28

Abstract: A population of antibodies, wherein less than 80% of the oligosaccharides covalently attached to the population of the antibodies via N297 residues thereof comprise a core fucose residue; and wherein the population of the antibodies comprises an antibody which Fc region comprises K338A and T437R mutations, or K248E and T437R mutations.